Wall Street brokerages forecast that Masimo (NASDAQ:MASI) will announce $0.70 earnings per share (EPS) for the current quarter, Zacks reports. Three analysts have provided estimates for Masimo’s earnings, with estimates ranging from $0.68 to $0.73. Masimo posted earnings per share of $0.57 during the same quarter last year, which indicates a positive year over year growth rate of 22.8%. The company is scheduled to announce its next earnings results after the market closes on Wednesday, May 2nd.
According to Zacks, analysts expect that Masimo will report full-year earnings of $2.81 per share for the current fiscal year, with EPS estimates ranging from $2.80 to $2.82. For the next financial year, analysts forecast that the business will post earnings of $2.94 per share, with EPS estimates ranging from $2.91 to $2.97. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Masimo.
Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The company had revenue of $225.20 million for the quarter, compared to the consensus estimate of $201.54 million. During the same quarter in the previous year, the company earned $0.46 EPS. Masimo’s quarterly revenue was up 22.9% compared to the same quarter last year.
MASI has been the topic of a number of research reports. Barclays initiated coverage on shares of Masimo in a research report on Friday, March 9th. They set an “overweight” rating and a $97.00 target price on the stock. Zacks Investment Research downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. BidaskClub upgraded shares of Masimo from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Finally, Piper Jaffray reiterated a “hold” rating and set a $91.00 target price on shares of Masimo in a research report on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $101.00.
Shares of Masimo stock traded up $0.36 during trading on Wednesday, reaching $88.77. 193,109 shares of the company traded hands, compared to its average volume of 542,879. Masimo has a 1-year low of $80.69 and a 1-year high of $104.71. The company has a market capitalization of $4,478.42, a PE ratio of 36.20, a PEG ratio of 2.28 and a beta of 0.94.
In other Masimo news, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $93.07, for a total transaction of $186,140.00. Following the completion of the sale, the director now owns 68,249 shares in the company, valued at approximately $6,351,934.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jon Coleman sold 29,303 shares of the business’s stock in a transaction on Thursday, March 29th. The shares were sold at an average price of $87.50, for a total transaction of $2,564,012.50. Following the sale, the insider now owns 20,504 shares of the company’s stock, valued at approximately $1,794,100. The disclosure for this sale can be found here. Insiders have sold a total of 45,403 shares of company stock valued at $4,040,693 in the last 90 days. 13.10% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in MASI. New York State Common Retirement Fund increased its stake in Masimo by 7.8% during the 3rd quarter. New York State Common Retirement Fund now owns 63,410 shares of the medical equipment provider’s stock valued at $5,489,000 after purchasing an additional 4,594 shares in the last quarter. Legal & General Group Plc increased its stake in Masimo by 15.6% during the 3rd quarter. Legal & General Group Plc now owns 41,189 shares of the medical equipment provider’s stock valued at $3,560,000 after purchasing an additional 5,566 shares in the last quarter. Jane Street Group LLC bought a new stake in Masimo during the 3rd quarter valued at $317,000. Ladenburg Thalmann Financial Services Inc. increased its stake in Masimo by 8.5% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,650 shares of the medical equipment provider’s stock valued at $835,000 after purchasing an additional 759 shares in the last quarter. Finally, Janney Montgomery Scott LLC increased its stake in Masimo by 6.0% during the 3rd quarter. Janney Montgomery Scott LLC now owns 17,275 shares of the medical equipment provider’s stock valued at $1,495,000 after purchasing an additional 980 shares in the last quarter. Institutional investors and hedge funds own 82.77% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Brokerages Expect Masimo (MASI) to Post $0.70 Earnings Per Share” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://ledgergazette.com/2018/04/18/brokerages-expect-masimo-masi-to-post-0-70-earnings-per-share.html.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.